Sales grew 18% last year. In the case of Kogenate, the patent isn’t for the compound itself, but rather for its hard‐to‐replicate manufacturing process. That patent expires in 2017. That’s why, starting in the first quarter of 2016, Bayer is gradually replacing Kogenate with Kovaltry, a similar but longer‐acting hemophilia drug that magically uses the same manufacturing facilities. In 2018, Bayer will add Damoctocog alfa to the hemophilia franchise, putting itself one more step ahead of generic competition.